Ruben Mesa, Md On Myelofibrosis

Ruben Mesa, MD: Myelofibrosis Patients Frequently Present Symptoms

Ruben Mesa, MD on Myelofibrosis (Full Interview)

Rare Disease Report

Ruben Mesa, MD Discusses Pathophysiology and Treatment of Myelofibrosis

Rare Disease Report

Dr. Ruben Mesa Discusses ASCO 2023 Updates from the SIMPLIFY Trials in Myelofibrosis

Dr Ruben Mesa Outlines the Quality of Life Impact of Myelofibrosis

Ruben Mesa, MD - The History of MPNs

MPN Advocacy & Education International

Ruben Mesa, MD: Ruxolitinib as a Myelofibrosis Treatment

Dr. Ruben Mesa on COMFORT-1 for Myelofibrosis

ASH Impact Series: Ruben Mesa, MD - Examining the Current Role of Ruxolitinib in Myelofibrosis

American Society of Hematology

Ruben Mesa, MD: Momelotinib Non-Inferior to Ruxolitinib in Myelofibrosis

American Society of Hematology

Clinical outcomes for patients with myelofibrosis after transition from ruxolitinib to momelotinib

VJHemOnc – Video Journal of Hematology & HemOnc

Ruben Mesa, MD Discusses Supportive Care for Myelofibrosis Patients

Rare Disease Report

Ruben A. Mesa, MD: Treating Myelofibrosis After Ruxolitinib “Failure”

American Society of Hematology

SIMPLIFY studies: analysis of the meaningful symptomatic change in patients with myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Dr Ruben Mesa-Myelofibrosis and Advancing MPNs: Current and Future Approaches

MPN Advocacy & Education International

Ruben Mesa on the Current State of Ruxolitinib Research in Myelofibrosis

The Institute for Continuing Healthcare Education

Dr Ruben Mesa Discusses Better Understanding Symptoms in MPNs

Dr. Mesa on Ruxolitinib Vs Fedratinib in Myelofibrosis Treatment

Dr. Mesa on the Utility of Ruxolitinib Versus Fedratinib in Myelofibrosis

For Myelofibrosis Patients: The Latest on Promising Treatments from Top Specialist | Dr. Ruben Mesa

The Patient Story